iX Biopharma LTD achieved robust financial performance with significant revenue and gross profit growth, alongside reduced adjusted EBITDA losses. The Group is strategically scaling its wellness business and accelerating its pharmaceutical pipeline's market entry, leveraging unique sublingual technologies.

• Discover how proprietary sublingual technologies are revolutionising drug delivery and market potential

• Explore a key wellness product's strategic expansion into a dynamic longevity market

• Learn about the accelerated commercialisation of pharmaceutical assets through targeted partnerships